A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes

Kishiyama, Christopher M.; Burdick, Patricia; Cobry, Erin; Gage, Victoria; Messer, Laurel H.; McFann, Kim; Chase, H. Peter

doi:10.1542/peds.2008-3750

Cited by 20 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heptulla et al [55] have shown that co-administration of amylin analogue with insulin to a small cohort of adolescent with type 1 diabetes induced a larger reduction in proprandial hyperglycemia, with a concomitant reduction in the level of glucagon when compared to insulin monotherapy. Pramlintide, given subcutaneously at a dose of 30 g per meal, significantly reduced body weight, HbA1c values and even the dosage of insulin [56].…”

Section: J) Pramlintidementioning

confidence: 96%

Current Updates in the Medical Management of Obesity

Khan¹,

Raza²,

Khan³

et al. 2012

EMI

View full text Add to dashboard Cite

Obesity is a chronic medical condition that is expected to become an indirect but leading cause of mortality and morbidity. Obesity results in type 2 diabetes mellitus, insulin resistance, hypertension, dyslipidemia, coronary heart disease. These factors contribute to cardiovascular disease that is a leading cause of death. Therefore, the approach to obesity therapy should be designed to reduce cardiovascular disease risk and mortality. Diet and lifestyle changes remain the cornerstones of therapy for obesity, but the resultant weight loss is often small. For more effective weight loss, individuals have shown to benefit from anti-obesity medications. Anti-Obesity therapy is considered for individuals with a body mass index greater than 30 kg/m2 or ranging from 25 to 30 kg/m2, or individuals with co-morbid conditions. Recent anti-obese medications affect biological mechanisms that suppress appetite and absorb nutrients to regulate body weight. In this review, we discuss the FDA approved anti-obesity drugs and recent patents which include phentermine/topiramate, pramlintide, lorcaserin, AOD9604, oleoyl-estrone, trk-beta antagonists and melanin concentrating hormone that can reduce adiposity at the molecular level.

show abstract

Section: J) Pramlintidementioning

confidence: 96%

Current Updates in the Medical Management of Obesity

Khan¹,

Raza²,

Khan³

et al. 2012

EMI

View full text Add to dashboard Cite

show abstract

“…Most trials have been short-term, offering minimal information on long-term efficacy and safety of pramlintide. [51][52][53][54][55] Metformin is the diabetes therapy with the most evidence for efficacy and safety in obese pediatric patients, although its effects are modest. GLP-1 agonists are also well-tolerated and may offer greater efficacy for weight loss than metformin in pediatric patients in the future as additional clinical trials are completed.…”

Section: Future Diabetes Therapiesmentioning

confidence: 99%

Pharmacological Management of Obesity in Pediatric Patients

Boland

Harris

2014

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…155 The main adverse effects are nausea and abdominal discomfort. Although small trials of pramlintide have been reported in adolescents with type 1 diabetes, 156, 157 no pediatric or adolescent weight loss studies have been conducted.…”

Section: Current Pharmacotherapeutic Options For Obesity Treatmentmentioning

confidence: 99%

Pharmacotherapy for childhood obesity: present and future prospects

Sherafat-Kazemzadeh

Yanovski

2012

Int J Obes

View full text Add to dashboard Cite

Pediatric obesity is a serious medical condition associated with significant comorbidities during childhood and adulthood. Lifestyle modifications are essential for treating children with obesity, yet many have insufficient response to improve health with behavioral approaches alone. This review summarizes the relatively sparse data on pharmacotherapy for pediatric obesity and presents information on obesity medications in development. Most previously studied medications demonstrated, at best, modest effects on body weight and obesity-related conditions. It is to be hoped that the future will bring new drugs targeting specific obesity phenotypes that will allow clinicians to use etiology-specific, and therefore more effective, anti-obesity therapies.

show abstract

A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes

Abstract: Pramlintide can help some adolescents to decrease postprandial hyperglycemia, HbA1c values, body weight, and insulin dosages. Additional large-scale trials should now be considered.

Cited by 20 publications

References 13 publications

Current Updates in the Medical Management of Obesity

Current Updates in the Medical Management of Obesity

Pharmacological Management of Obesity in Pediatric Patients

Pharmacotherapy for childhood obesity: present and future prospects

Contact Info

Product

Resources

About